# A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct07740720/  
OnCo record `nct07740720` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of dostarlimab in colorectal cancer, run by GlaxoSmithKline, not yet recruiting.

## Summary

A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer is a phase 3, interventional study registered as NCT07740720 by GlaxoSmithKline, with a registry enrolment figure of 90 participants, started 2026-09-17 and due to reach its primary completion in 2029-12-12. Interventions recorded: Dostarlimab. Conditions listed: Neoplasms, Rectal. Primary outcome: Percentage of participants who achieve clinical complete response (cCR) amongst participants who receive > 9 cycles (> 6 months) of dostarlimab monotherapy by investigator assessment. Colorectal eligibility wording from the registry: "* Has histologically confirmed Stage II to III (T3-T4, N0, or T any, N+) locally advanced rectal adenocarcinoma". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: DuraSTAR
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07740720
- Phase: 3
- Setting: A Phase 3b, Open-label Study Investigating the Duration of Neoadjuvant Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer
- Sponsor: GlaxoSmithKline
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07740720: https://clinicaltrials.gov/study/NCT07740720

## Connected records

- cancers: [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07740720.json